9 hrs ago
Pharmacyclics Reports Second Quarter 2014 Results
Pharmacyclics, Inc. today reported financial results and recent developments for the quarter ended June 30, 2014.
Tue Jul 29, 2014
Stocks On the Move: Corning Incorporated, Oshkosh Corporation, and Pharmacyclics, Inc.
U.S. stocks are marginally higher this afternoon, with solid gains for DuPont and Merck & Co., Inc. propping up the Dow.
Mon Jul 28, 2014
Pharmacyclics Announces Date of Conference call to discuss Financial...
Pharmacyclics, Inc. today announced that it will hold a conference call and audio webcast to discuss financial results for the second quarter of 2014 after the NASDAQ Market closes on Thursday, July 31, 2014 at 4:30 p.m. ET.
In Europe, two drugs will compete to treat rare blood cancer
In Europe, two Bay Area pharmaceutical companies will go head-to-head over new drugs that both treat a rare blood cancer, chronic lymphocytic leukemia, in patients whose disease has returned.
U.S. FDA Grants Regular (Full) Approval For Pharmacyclics, Inc.'s...
This is the first full FDA approval for IMBRUVICA, and was granted within six months after the accelerated approval for patients with previously treated CLL in February 2014.
Fri Jul 25, 2014
EMA recommends full marketing approval for IMBRUVICA in the European Union
Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA in the European Union.
Thu Jul 24, 2014
Profits and capacity utilisation up at Lonza in H1 thanks to pharma
Lonza saw profits and capacity utilisation improve in the first half of 2014 with new pharma and biopharma supply contracts and ongoing restructuring being the key drivers.
Biomedical engineer looks at new applications for novel lupus drug
Expanding on his work with a new drug that successfully treated lupus in mice, a biomedical engineer at the University of Houston has received a $250,000 grant to expand his research to a new version of the drug in an effort to treat a wider range of autoimmune diseases.
Wed Jul 23, 2014
The Motley Fool
Is Gilead About to Crush Pharmacyclics Stock?
However, before investors begin abandoning Pharmacyclics shares thinking that Zydelig will regulate Imbruvica to the back-burner in chronic lymphocytic leukemia, or CLL, they should recognize that Imbruvica may do very well on its own despite the threat.
Pharmacyclics estimates raised ahead of Q2 report at Goldman
Pharmacyclics estimates raised ahead of Q2 report at Goldman Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data.